Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/27 06:44:26 am
443.35 DKK   -1.06%
01/26NOVO NORDISK : Goldman Sachs keeps its Buy rating
01/26NOVO NORDISK : JP Morgan gives a Buy rating
01/25NOVO NORDISK A/S : – Share repurchase programme
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : – Share repurchase programme

11/23/2020 | 08:37am EST

Bagsværd, Denmark, 23 November 2020– On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme initiated 3 November 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 4 November 2020 to 1 February 2021.

Since the announcement as of 16 November 2020, the following transactions have been made:

 Number of
B shares
purchase price
value, DKK
Accumulated, last announcement905,000 393,979,797
16 November 2020115,000425.3248,911,525
17 November 2020115,000424.3748,802,440
18 November 2020120,000422.2350,667,116
19 November 2020120,000423.2750,792,429
20 November 2020120,000424.2850,913,888
Accumulated under the programme1,495,000 644,067,195

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 35,018,659 B shares of DKK 0.20 as treasury shares, corresponding to 1.5% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 20 November 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 35,080,522 B shares at an average share price of DKK 424.95 per B share equal to a transaction value of DKK 14,907,496,665.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com
Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com

Company announcement no. 72 / 2020


  • CA201123_Safe_Harbour

© OMX, source OMX

All news about NOVO NORDISK A/S
01/26NOVO NORDISK : Goldman Sachs keeps its Buy rating
01/26NOVO NORDISK : JP Morgan gives a Buy rating
01/25NOVO NORDISK A/S : – Share repurchase programme
01/21NOVO NORDISK A/S : Files For US Regulatory Approval For Increased Dose Of Type 2..
01/20NOVO NORDISK A/S : Applies for Label Expansion to Introduce New Dosage for Ozemp..
01/20NOVO NORDISK A/S : files for regulatory approval in the US of once-weekly semagl..
01/20NOVO NORDISK : Credit Suisse gives a Neutral rating
01/20NOVO NORDISK : Jefferies remains a Sell rating
01/18NOVO NORDISK : Buy rating from JP Morgan
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy..
More news
Sales 2020 127 B 20 717 M 20 717 M
Net income 2020 42 017 M 6 853 M 6 853 M
Net cash 2020 9 589 M 1 564 M 1 564 M
P/E ratio 2020 24,9x
Yield 2020 2,00%
Capitalization 1 036 B 169 B 169 B
EV / Sales 2020 8,08x
EV / Sales 2021 7,72x
Nbr of Employees 44 326
Free-Float 75,1%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 28
Average target price 456,33 DKK
Last Close Price 448,10 DKK
Spread / Highest target 22,7%
Spread / Average Target 1,84%
Spread / Lowest Target -31,9%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S5.03%169 316
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035